OncoMatch/Clinical Trials/NCT06645808

PET-imaging of Two Vartumabs in Patients With Solid Tumors

Official title: The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET/CT Molecular Imaging Basket Trial

Is NCT06645808 recruiting? Yes, currently enrolling (Oct 2026). This Early Phase 1 trial studies multiple treatments including 89Zr-DFO-N-Suc-F8scFv and 89Zr-DFO-N-Suc-C9scFv for solid tumor.

Treatment: 89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv — VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS). Oncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues. VAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.